NSCLC Patients

May 08, 2026

Non-small Cell Lung Cancer (NSCLC) treatment has evolved from a chemotherapy-dominated approach to a biomarker-driven paradigm, enabled by the identification of multiple actionable alterations, including the EGFR signaling pathway, ALK, BRAF, RET, NTRK, HER2, KRAS, ROS1, and MET alterations. This shift has expanded...

Mar 29, 2024

In the realm of cancer treatment, the development of targeted therapies has been nothing short of revolutionary. Among these advancements, EGFR inhibitors have emerged as a powerful weapon in the fight against certain types of cancer. EGFR, or Epidermal Growth Factor Receptor, is a protein found on the surface of c...

Mar 12, 2020

The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC)  The drug has been recommended for its use in NSCLC patients with epidermal growth factor (EGFR) Exon 20 insertion mutations, categorized wit...